BRIGHT MINDS BIOSCIENCES INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
other
SEC Category
Emerging growth company
State of Incorporation
British Columbia, Canada
Business Address
19 VESTRY STREET, NEW YORK, NY, 10013
Mailing Address
19 VESTRY STREET, NEW YORK, NY, 10013
Phone
6474072515
Fiscal Year End
0930
EIN
000000000
Financial Overview
FY2024
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| 6-K Foreign company current report | February 13, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 6, 2026 | View on SEC |
| 6-K Foreign company current report | January 9, 2026 | View on SEC |
| 6-K Foreign company current report | January 9, 2026 | View on SEC |
| 424B5 Prospectus supplement | January 9, 2026 | View on SEC |
| 6-K Foreign company current report | January 8, 2026 | View on SEC |
| 6-K Foreign company current report | January 7, 2026 | View on SEC |
Annual Reports
40-F
December 23, 2025
- BRIGHT MINDS BIOSCIENCES INC. (DRUG) concluded its fiscal year on September 30, 2025.
- The company reported 7,635,789 common shares outstanding as of the fiscal year-end.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.